ABOLISH
Research type
Research Study
Full title
INTERNATIONAL, MULTICENTRE, OBSERVATIONAL, PROSPECTIVE, LONGITUDINAL STUDY TO ASSESS THE EFFECTIVENESS OF ABOBONT-A INJECTIONS FOR ADULT LOWER LIMB SPASTICITY IN A REAL LIFE COHORT (ABOLISH)
IRAS ID
274127
Contact name
Stephen Ashford
Contact email
Sponsor organisation
Ipsen Pharma SAS
Clinicaltrials.gov Identifier
244522, Parexel study reference
Duration of Study in the UK
2 years, 5 months, 0 days
Research summary
Patients diagnosed with lower limb spasticity (stiffness in lower limb/leg) and treated with abobotulinumtoxin A will be enrolled in this observational study. During this research study, Sponsor will collect information about patient’s condition and treatment that may improve the way patients with spasticity are treated. The aim is to better understand how patients suffering from lower limb spasticity are treated in real life with abobotulinumtoxin A (e.g. which muscles are injected, what doses are used, if physical therapy is in place). The study will look at the treatment goals set between patient and his doctor and how these are achieved over the study period of up to 16 months, and will also evaluate how the lower limb spasticity and the treatment received impact the patient's quality of life.
REC name
North West - Haydock Research Ethics Committee
REC reference
20/NW/0309
Date of REC Opinion
10 Jul 2020
REC opinion
Favourable Opinion